<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548735" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548735/" /><meta name="ncbi_pagename" content="Plicamycin - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Plicamycin - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Plicamycin" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/02/19" /><meta name="citation_pmid" content="31644044" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548735/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Plicamycin" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/02/19" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548735/" /><meta name="description" content="Plicamycin, which was formerly known as mithramycin, is an antibiotic that is used as an anticancer agent in the therapy of testicular and germ cell cancers. Plicamycin causes acute hepatic injury that arises within days of starting therapy, but is usually transient and asymptomatic and rarely leads to jaundice. Plicamycin has not been approved for use as cancer chemotherapy in the United States, but continues to be used on an investigational basis." /><meta name="og:title" content="Plicamycin" /><meta name="og:type" content="book" /><meta name="og:description" content="Plicamycin, which was formerly known as mithramycin, is an antibiotic that is used as an anticancer agent in the therapy of testicular and germ cell cancers. Plicamycin causes acute hepatic injury that arises within days of starting therapy, but is usually transient and asymptomatic and rarely leads to jaundice. Plicamycin has not been approved for use as cancer chemotherapy in the United States, but continues to be used on an investigational basis." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548735/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Plicamycin/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548735/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B35F30466A1110000000007EA0252.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548735_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548735_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Plerixafor/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/ShouWuPian/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548735_"><span class="title" itemprop="name">Plicamycin</span></h1><p class="small">Last Update: <span itemprop="dateModified">February 19, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Plicamycin.OVERVIEW"><h2 id="_Plicamycin_OVERVIEW_">OVERVIEW</h2><div id="Plicamycin.Introduction"><h3>Introduction</h3><p>Plicamycin, which was formerly known as mithramycin, is an antibiotic that is used as an anticancer agent in the therapy of testicular and germ cell cancers. Plicamycin causes acute hepatic injury that arises within days of starting therapy, but is usually transient and asymptomatic and rarely leads to jaundice. Plicamycin has not been approved for use as cancer chemotherapy in the United States, but continues to be used on an investigational basis.</p></div><div id="Plicamycin.Background"><h3>Background</h3><p>Plicamycin (plye&#x0201d; ka mye&#x02019; sin), which was formerly known as mithramycin, is an antineoplastic antibiotic that was first isolated from fermentation extracts of Streptomyces plicatus. It acts by binding to helical double-stranded DNA and blocking RNA synthesis. It has potent antitumor effects in vitro and has been evaluated in several solid tumors in humans. Because of its toxicities (including hepatotoxicities), it has not been approved for use in the United States. Nevertheless, plicamycin has distinctive and sometimes potent activities against germ cell and testicular cancers and continues to be investigated as an experimental therapy in patients with advanced and resistant forms of cancer. Plicamycin is also effective in reducing hypercalcemia associated with malignancy, probably by inhibition of osteoblast function, but its use has been replaced by less toxic approaches such as corticosteroids and bisphosphonates. For the treatment of cancer, plicamycin is administered intravenously in doses of 25 to 50 &#x003bc;g/kg daily for 5 to10 days in 2 to 6 monthly courses. Side effects of plicamycin are common and often dose limiting, including bone marrow suppression, irritability, agitation, gastrointestinal upset, diarrhea, nausea, anorexia, weakness, fever, rash, epistaxis, bruising and hemorrhage.</p></div><div id="Plicamycin.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Chemotherapy with plicamycin causes serum enzyme elevations in almost all patients who are treated for more than 1 or 2 days and who are monitored during therapy. Serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a>, <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> and LDH values begin to rise within 3 days of the first infusion and peak within 7 to 10 days at levels of 5 to 500 times the upper limit of the normal range (ULN). The elevations, however, are transient and resolve within 1 to 3 weeks and are rarely associated with symptoms or jaundice. Liver biopsies taken during these episodes usually demonstrate centrolobular necrosis and congestion. With repeated courses, elevations continue to occur generally to the same or lesser degree. A single instance of acute liver failure arising within days of therapy that was suggestive of ischemic hepatitis or sinusoidal obstruction syndrome has been reported in a patient treated with full doses of plicamycin for 4 days for nonmalignant hypercalcemia. Otherwise, the serum enzyme elevations, despite being moderate to severe, are transient and benign.</p><p>Likelihood score: A[H] (well known cause of clinically apparent liver injury with high dose intravenous treatment).</p></div><div id="Plicamycin.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>Plicamycin appears to be a direct, intrinsic hepatotoxin as the injury can be produced in animal models and occurs in almost all patients. The injury is likely to be dose related and is not more severe or more rapid in onset with rechallenge. Experimental studies suggest that the hepatotoxicity of plicamycin relates to inhibition of farnesoid X receptor signaling leading to deregulation of bile acid homeostasis.</p></div><div id="Plicamycin.Outcome_and_Management"><h3>Outcome and Management</h3><p>The hepatic injury caused by plicamycin is usually reversible and requires no intervention. The hepatotoxicity of plicamycin has limited its usefulness, and it is considered contraindicated in patients with significant underlying liver disease.</p><p>Drug Class: <a href="/books/n/livertox/AntineoplasticAgents/">Antineoplastic Agents</a></p><p>Other Drugs in the Subclass, <a href="/books/n/livertox/CytotoxicAntibiotics/">Antibiotics, Cytotoxic</a>: <a href="/books/n/livertox/Bleomycin/">Bleomycin</a>, <a href="/books/n/livertox/Dactinomycin/">Dactinomycin</a>, <a href="/books/n/livertox/Daunorubicin/">Daunorubicin</a>, <a href="/books/n/livertox/DoxorubicinEpirubici/">Doxorubicin</a>, <a href="/books/n/livertox/DoxorubicinEpirubici/">Epirubicin</a>, <a href="/books/n/livertox/DoxorubicinEpirubici/">Idarubicin</a>, <a href="/books/n/livertox/Mitomycin/">Mitomycin</a>, <a href="/books/n/livertox/Mitoxantrone/">Mitoxantrone</a></p></div></div><div id="Plicamycin.CASE_REPORT"><h2 id="_Plicamycin_CASE_REPORT_">CASE REPORT</h2><div id="Plicamycin.Case_1_Marked_serum_aminotran"><h3>Case 1. Marked serum aminotransferase elevations during intravenous therapy with plicamycin.(<a class="bk_pop" href="#Plicamycin.REF.1">1</a>)</h3><p>A 63 year old man with intrathoracic mesothelioma participating in a phase II clinical trial at the Clinical Center of the National Institutes of Health was started on intravenous plicamycin (25 mcg/kg/day) and developed marked serum aminotransferase elevations within 2 days. He had no history of liver disease, alcohol abuse or known drug allergies and was known to have normal liver tests before starting treatment. He had no symptoms of liver injury and was not receiving other medications. <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> levels peaked at 4832 U/L and <a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> levels at 4889 U/L a day after stopping therapy and then fell promptly (Table). Tests for hepatitis A, B and C were negative as were routine autoantibodies. Ultrasound of the liver suggested heterogeneity of the liver texture, but showed no other abnormalities, liver masses or evidence of obstruction. A liver biopsy showed centrolobular (zone 3) necrosis and hemorrhage with mild inflammation and no fibrosis or steatosis. After his serum enzymes returned to normal, he was rechallenged with a lower dose of plicamycin (18 mcg/kg/day) and serum aminotransferase levels again rose within a few days, but to a lesser degree (peak ALT 454 U/L). No further therapy with plicamycin was given.</p><div id="Plicamycin.Key_Points"><h4>Key Points</h4><div id="Plicamycin.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548735/table/Plicamycin.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Plicamycin.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Plicamycin.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Plicamycin.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Plicamycin</td></tr><tr><th id="hd_b_Plicamycin.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Plicamycin.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hepatocellular (R=193)</td></tr><tr><th id="hd_b_Plicamycin.Tc_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Plicamycin.Tc_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1+ (never jaundiced)</td></tr><tr><th id="hd_b_Plicamycin.Tc_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Plicamycin.Tc_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 days</td></tr><tr><th id="hd_b_Plicamycin.Tc_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Plicamycin.Tc_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Complete recovery within 4 weeks</td></tr><tr><th id="hd_b_Plicamycin.Tc_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Plicamycin.Tc_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr></tbody></table></div></div></div><div id="Plicamycin.Laboratory_Values"><h4>Laboratory Values</h4><div id="Plicamycin.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548735/table/Plicamycin.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Plicamycin.Td_lrgtbl__"><table><thead><tr><th id="hd_h_Plicamycin.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Starting</th><th id="hd_h_Plicamycin.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Stopping</th><th id="hd_h_Plicamycin.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a><br />(U/L)</th><th id="hd_h_Plicamycin.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(U/L)</th><th id="hd_h_Plicamycin.Td_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a><br />(mg/dL)</th><th id="hd_h_Plicamycin.Td_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_Plicamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Plicamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Plicamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">32</td><td headers="hd_h_Plicamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">85</td><td headers="hd_h_Plicamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.3</td><td headers="hd_h_Plicamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Plicamycin started, INR 0.94</td></tr><tr><td headers="hd_h_Plicamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 day</td><td headers="hd_h_Plicamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Plicamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">37</td><td headers="hd_h_Plicamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">68</td><td headers="hd_h_Plicamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.6</td><td headers="hd_h_Plicamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INR 0.89</td></tr><tr><td headers="hd_h_Plicamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 days</td><td headers="hd_h_Plicamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Plicamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">48</td><td headers="hd_h_Plicamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">73</td><td headers="hd_h_Plicamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.3</td><td headers="hd_h_Plicamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Plicamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 days</td><td headers="hd_h_Plicamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Plicamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">714</td><td headers="hd_h_Plicamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">75</td><td headers="hd_h_Plicamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.3</td><td headers="hd_h_Plicamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ultrasound</td></tr><tr><td headers="hd_h_Plicamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 days</td><td headers="hd_h_Plicamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 day</td><td headers="hd_h_Plicamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4832</td><td headers="hd_h_Plicamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">71</td><td headers="hd_h_Plicamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.6</td><td headers="hd_h_Plicamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LDH 5995 U/L, liver biopsy</td></tr><tr><td headers="hd_h_Plicamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 days</td><td headers="hd_h_Plicamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 days</td><td headers="hd_h_Plicamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3510</td><td headers="hd_h_Plicamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">72</td><td headers="hd_h_Plicamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.9</td><td headers="hd_h_Plicamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INR 1.23</td></tr><tr><td headers="hd_h_Plicamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 days</td><td headers="hd_h_Plicamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 days</td><td headers="hd_h_Plicamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2144</td><td headers="hd_h_Plicamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">155</td><td headers="hd_h_Plicamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.9</td><td headers="hd_h_Plicamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Plicamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 days</td><td headers="hd_h_Plicamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 days</td><td headers="hd_h_Plicamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1522</td><td headers="hd_h_Plicamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">193</td><td headers="hd_h_Plicamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.7</td><td headers="hd_h_Plicamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Plicamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 month</td><td headers="hd_h_Plicamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 days</td><td headers="hd_h_Plicamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">37</td><td headers="hd_h_Plicamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">80</td><td headers="hd_h_Plicamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.6</td><td headers="hd_h_Plicamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Plicamycin restarted</td></tr><tr><td headers="hd_h_Plicamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">[3 days]</td><td headers="hd_h_Plicamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Plicamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">142</td><td headers="hd_h_Plicamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">86</td><td headers="hd_h_Plicamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.2</td><td headers="hd_h_Plicamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">INR 0.99</td></tr><tr><td headers="hd_h_Plicamycin.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">[5 days]</td><td headers="hd_h_Plicamycin.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Plicamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">454</td><td headers="hd_h_Plicamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">126</td><td headers="hd_h_Plicamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.4</td><td headers="hd_h_Plicamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Plicamycin.Td_1_1_1_1 hd_h_Plicamycin.Td_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Plicamycin.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;42</b></td><td headers="hd_h_Plicamycin.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;115</b></td><td headers="hd_h_Plicamycin.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Plicamycin.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Plicamycin.Comment"><h4>Comment</h4><p>The serial test results demonstrated the typical pattern of serum enzyme elevations with plicamycin therapy. The pattern is that of acute hepatic necrosis and is self-limited if therapy is stopped promptly. In this clinical trial, 10 of 12 treated patients developed hepatotoxicity with a pattern similar to the one shown. No patient developed jaundice, and symptoms, when present, were mild and nonspecific (mild nausea and abdominal discomfort).</p></div></div></div><div id="Plicamycin.PRODUCT_INFORMATION"><h2 id="_Plicamycin_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Plicamycin &#x02013; Generic, Mithracin&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antineoplastic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Plicamycin" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Plicamycin.CHEMICAL_FORMULA_AND_STRUCTUR"><h2 id="_Plicamycin_CHEMICAL_FORMULA_AND_STRUCTUR_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Plicamycin.Te" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548735/table/Plicamycin.Te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Plicamycin.Te_lrgtbl__"><table><tbody><tr><th id="hd_b_Plicamycin.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_b_Plicamycin.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO.</th><th id="hd_b_Plicamycin.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_b_Plicamycin.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr><tr><td headers="hd_b_Plicamycin.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Plicamycin</td><td headers="hd_b_Plicamycin.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134992646" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">18378-89-7</a></td><td headers="hd_b_Plicamycin.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C52-H76-O24</td><td headers="hd_b_Plicamycin.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134992646" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134992646" alt="image 134992646 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Plicamycin.CITED_REFERENCE"><h2 id="_Plicamycin_CITED_REFERENCE_">CITED REFERENCE</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="Plicamycin.REF.1">Sissung TM, Huang PA, Hauke RJ, McCrea EM, Peer CJ, Barbier RH, Strope JD, et al.  Severe hepatotoxicity of mithramycin therapy caused by altered expression of hepatocellular bile transporters. <span><span class="ref-journal">Mol Pharmacol. </span>2019;<span class="ref-vol">96</span>:158–67.</span> [<a href="/pmc/articles/PMC6608607/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6608607</span></a>] [<a href="/pubmed/31175181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31175181</span></a>]</div></dd></dl></div><div id="Plicamycin.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Plicamycin_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 19 February 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Plicamycin.REF.zimmerman.1999">Zimmerman HJ. Antibiotics. Hepatotoxic effects of oncotherapeutic and immunosuppressive agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 694-8.<div><i>(Expert review of hepatotoxicity published in 1999 mentions that mithramycin [plicamycin] is "highly toxic" and that hepatic injury occurs in 25-100% of patients, and is marked by very high elevations in ALT levels).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.deleve.2013">DeLeve LD. Cancer chemotherapy. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 541-68.<div><i>(Review of hepatotoxicity of cancer chemotherapeutic agents mentions that mithramycin hepatotoxicity is uncommon with dosing used for hypercalcemia, but frequent with daily dosing used in cancer).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.wellstein.2018">Wellstein A, Giaccone G, Atkins MB, Sausville EA. Cytotoxic agents. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1167-203.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.kofman.1964.938">Kofman S, Medrek TJ, Alexancer RW. Mithramycin in the treatment of embryonal cancer. <span><span class="ref-journal">Cancer. </span>1964;<span class="ref-vol">17</span>:938–48.</span> [<a href="/pubmed/14179556" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14179556</span></a>]<div><i>(Retrospective analysis of 26 patients with embryonic cell cancers treated with plicamycin found dramatic responses in a few patients, but therapy was limited by toxicities, largely to the bone marrow, no mention of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.brown.1965.111">Brown JH, Kennedy BJ. Mithramycin in the treatment of disseminated testicular neoplasms. <span><span class="ref-journal">N Engl J Med. </span>1965;<span class="ref-vol">272</span>:111–8.</span> [<a href="/pubmed/14224214" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14224214</span></a>]<div><i>(Among 12 patients with testicular cancer treated with 2 to 6 courses of plicamycin, 7 had objective regression, all had hepatotoxicity with ALT rising after 3-5 days to as high as 21,000 U/L, then resolving with no jaundice and no deaths from liver disease).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.morrison.1967.468">Morrison RK, Brown DE, Oleson JJ. A toxicologic study of mithramycin. <span><span class="ref-journal">Toxicol Appl Pharmacol. </span>1967;<span class="ref-vol">11</span>:468–81.</span> [<a href="/pubmed/4968193" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4968193</span></a>]<div><i>(In monkeys and dogs, doses of plicamycin of 0.1 mcg/kg caused marked serum ALT elevations within 5-7 days).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.ream.1968.1030">Ream NW, Perlia CP, Wolter J, Taylor SG 3rd. Mithramycin therapy in disseminated germinal testicular cancer. <span><span class="ref-journal">JAMA. </span>1968;<span class="ref-vol">204</span>:1030–6.</span> [<a href="/pubmed/5694748" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5694748</span></a>]<div><i>(Among 30 patients with disseminated testicular cancer treated with plicamycin, 9 had an objective response, ALT elevations occurred with each course but returned to normal within 2-3 weeks and no patient developed jaundice; autopsy in 1 patient showed "toxic fatty metamorphosis").</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.ansfield.1969.283">Ansfield FJ. Clinical studies with mithramycin. <span><span class="ref-journal">Oncology. </span>1969;<span class="ref-vol">23</span>:283–8.</span> [<a href="/pubmed/5817464" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5817464</span></a>]<div><i>(Among 46 patients with various solid tumors treated with plicamycin [78 courses] in varying doses, moderate-to-severe toxicity occurred in all and 4 patients died; 11 of 22 patients who were monitored had ALT elevations, but all reversed within 1 month).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.ryan.1970.1153">Ryan WG, Schwartz TB, Northrop G. Experiences in the treatment of Paget's disease of bone with mithramycin. <span><span class="ref-journal">JAMA. </span>1970;<span class="ref-vol">213</span>:1153–7.</span> [<a href="/pubmed/5468261" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5468261</span></a>]<div><i>(Among 15 patients with Paget disease of bone treated with plicamycin, serum enzyme elevations occurred, the most sensitive enzyme being isocitric dehydrogenase [ICD], which rose up to 160 times ULN).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.kennedy.1970.494">Kennedy BJ. Metabolic and toxic effects of mithramycin during tumor therapy. <span><span class="ref-journal">Am J Med. </span>1970;<span class="ref-vol">49</span>:494–503.</span> [<a href="/pubmed/4320120" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4320120</span></a>]<div><i>(Among 58 patients with advanced cancers treated with plicamycin, side effects were common including malaise, gastrointestinal upset, fever, headache, irritability, agitation, rash, stomatitis, epistaxis and hemorrhage; ALT or AST elevations occurred in all [up to 8,000 U/L], usually resolving rapidly).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.kennedy.1970.755">Kennedy BJ. Mithramycin therapy in advanced testicular neoplasms. <span><span class="ref-journal">Cancer. </span>1970;<span class="ref-vol">26</span>:755–66.</span> [<a href="/pubmed/5506598" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5506598</span></a>]<div><i>(Among 44 patients with advanced testicular cancer treated with plicamycin, alternate day regimens were more effective and less toxic than standard daily regimens of administration, but all patients had transient LDH elevations during therapy).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.foley.1972.439">Foley JF, Lemon HM, Miller DM, Kessinger A. The treatment of metastatic testicular tumors. <span><span class="ref-journal">J Urol. </span>1972;<span class="ref-vol">108</span>:439–42.</span> [<a href="/pubmed/4115279" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4115279</span></a>]<div><i>(Among 11 patients with testicular cancer treated with plicamycin and 7 with dactinomycin, all developed transient serum enzyme elevations).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.ellas.1972.431">Ellas EG, Reynoso G, Mittelman A. Control of hypercalcemia with mithramycin. <span><span class="ref-journal">Ann Surg. </span>1972;<span class="ref-vol">175</span>:431–5.</span> [<a href="/pmc/articles/PMC1355190/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1355190</span></a>] [<a href="/pubmed/4263259" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4263259</span></a>]<div><i>(Among 12 patients with hypercalcemia treated with plicamycin [25 mcg/kg for 1 to 5 days], calcium levels fell in all, AST values rose [77-1250 U/L] in those treated for 3-5 days, but not in those given 1-2 doses only).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.ryan.1973.1319">Ryan WG. Mithramycin in Paget's disease of bone. <span><span class="ref-journal">Lancet. </span>1973;<span class="ref-vol">1</span>(7815):1319.</span> [<a href="/pubmed/4126107" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4126107</span></a>]<div><i>(Among 97 patients with Paget disease treated with plicamycin, all had increases in serum enzymes, but the abnormalities resolved promptly, and no patient had evidence of residual liver damage).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.fraisse.1980.281">Fraisse F, Marche C, Gibert C, Coquin Y, Vachon F. <span><span class="ref-journal">Ann Med Interne (Paris). </span>1980;<span class="ref-vol">131</span>:281–4.</span> [Acute hepatic necrosis and hemorrhagic syndrome leading to a fatal outcome during treatment of hypercalcemia with mithramycin (author's transl)] [<a href="/pubmed/6449897" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6449897</span></a>]<div><i>(26 year old woman treated with plicamycin for nonmalignant hypercalcemia for 4 days [total dose of 5 mg] developed marked increase in ALT [1,600 U/L], coagulopathy, thrombocytopenia, hemorrhage and shock, dying within days of multiorgan failure).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.green.1984.1379">Green L, Donehower RC. Hepatic toxicity of low doses of mithramycin in hypercalcemia. <span><span class="ref-journal">Cancer Treat Rep. </span>1984;<span class="ref-vol">68</span>:1379–81.</span> [<a href="/pubmed/6238672" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6238672</span></a>]<div><i>(Among 67 patients with malignant hypercalcemia treated with plicamycin, AST elevations occurred in all, starting within 2 days and resolving within 2-3 weeks; no patient was jaundiced and repeat courses caused similar reactions which were not more severe).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.h_mon.1985.301">H&#x000e9;mon Y, Martin C, Auffray JP, Bonneru JJ, Brunet C, Farisse J. <span><span class="ref-journal">Ann Fr Anesth Reanim. </span>1985;<span class="ref-vol">4</span>:301–3.</span> [Acute fatal hepatorenal failure during treatment with mithramycin] French. [<a href="/pubmed/3160268" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3160268</span></a>]<div><i>(64 year old woman with hypercalcemia developed acute liver failure two days after an infusion of mithramycin and one day after parathyroid surgery).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.sznol.1987.237">Sznol M, Ohnuma T, Holland JF. Hepatic toxicity of drugs used for hematologic neoplasia. <span><span class="ref-journal">Semin Liver Dis. </span>1987;<span class="ref-vol">7</span>:237–56.</span> [<a href="/pubmed/3317861" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3317861</span></a>]<div><i>(Overview of hepatotoxicity of antineoplastic agents, mentions that mithramycin displays dose related hepatotoxicity in animals and in humans marked by aminotransferase and lactic dehydrogenase elevations).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.davidson.2001.s8">Davidson TG. Conventional treatment of hypercalcemia of malignancy. <span><span class="ref-journal">Am J Health Syst Pharm. </span>2001;<span class="ref-vol">58</span> Suppl 3:S8–15.</span> [<a href="/pubmed/11757206" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11757206</span></a>]<div><i>(Review of therapy of malignant hypercalcemia mentions that plicamycin can be effective, but has a variable and unpredictable duration of response and is usually reserved for cases in which other therapies have failed).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network (DILIN).  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, several cases were attributed to antineoplastic agents [such as mercaptopurine, cyclophosphamide, docetaxel, temozolomide, bortezomib and imatinib], but none to mithramycin).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group.  Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, including 2 attributed to antineoplastic agents, 1 to melphalan and 1 to gemtuzumab, but none to mithramycin).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.hern_ndez.2014.231">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al.  Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Among 176 reports of drug induced liver injury from Latin America published between 1996 and 2012, ten were attributed to antineoplastic agents, but none to plicamycin).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.chalasani.2015">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52. e7. [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 49 cases were attributed to antineoplastic agents, but none to plicamycin).</i></div></div></li><li><div class="bk_ref" id="Plicamycin.REF.sissung.2019.158">Sissung TM, Huang PA, Hauke RJ, McCrea EM, Peer CJ, Barbier RH, Strope JD, et al.  Severe hepatotoxicity of mithramycin therapy caused by altered expression of hepatocellular bile transporters. <span><span class="ref-journal">Mol Pharmacol. </span>2019;<span class="ref-vol">96</span>:158–67.</span> [<a href="/pmc/articles/PMC6608607/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6608607</span></a>] [<a href="/pubmed/31175181" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31175181</span></a>]<div><i>(12 patients with various malignancies were treated with 20 cycles of intravenous plicamycin of whom 10 developed ALT elevations that were above 5 times ULN in 8; molecular analyses suggested that the plicamycin hepatotoxicity was mediated by inhibition of FXR signaling: Case 1).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548735</span><span class="label">PMID: <a href="/pubmed/31644044" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31644044</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Plerixafor/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/ShouWuPian/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548735&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548735/?report=reader">PubReader</a></li><li><a href="/books/NBK548735/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548735" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548735" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Plicamycin. [Updated 2020 Feb 19].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548735/pdf/Bookshelf_NBK548735.pdf">PDF version of this page</a> (113K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=Plicamycin+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Plicamycin: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=Plicamycin" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Plicamycin: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4859880" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4859880" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4859880" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/7700186" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Long-term follow-up of stage III testicular carcinoma treated with mithramycin (plicamycin).</a><span class="source">[Med Pediatr Oncol. 1995]</span><div class="brieflinkpop offscreen_noflow">Long-term follow-up of stage III testicular carcinoma treated with mithramycin (plicamycin).<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kennedy BJ, Torkelson JL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Med Pediatr Oncol. 1995 May; 24(5):327-8. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24468003" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">The anticancer antibiotic mithramycin-A inhibits TRPV1 expression in dorsal root ganglion neurons.</a><span class="source">[Neurosci Lett. 2014]</span><div class="brieflinkpop offscreen_noflow">The anticancer antibiotic mithramycin-A inhibits TRPV1 expression in dorsal root ganglion neurons.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Zavala K, Lee J, Chong J, Sharma M, Eilers H, Schumacher MA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Neurosci Lett. 2014 Aug 22; 578:211-6. Epub 2014 Jan 25.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/6252828" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">[Trial of the clinical use of mithramycin in treating testicular cancer].</a><span class="source">[Antibiotiki. 1980]</span><div class="brieflinkpop offscreen_noflow">[Trial of the clinical use of mithramycin in treating testicular cancer].<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Trofimova NB. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Antibiotiki. 1980 Oct; 25(10):773-7. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26393942" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Expanding the Chemical Diversity of the Antitumoral Compound Mithramycin by Combinatorial Biosynthesis and Biocatalysis: The Quest for Mithralogs with Improved Therapeutic Window.</a><span class="source">[Planta Med. 2015]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Expanding the Chemical Diversity of the Antitumoral Compound Mithramycin by Combinatorial Biosynthesis and Biocatalysis: The Quest for Mithralogs with Improved Therapeutic Window.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Méndez C, González-Sabín J, Morís F, Salas JA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Planta Med. 2015 Oct; 81(15):1326-38. Epub 2015 Sep 21.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23902990" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mithramycin, an agent for developing new therapeutic drugs for neurodegenerative diseases.</a><span class="source">[J Pharmacol Sci. 2013]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mithramycin, an agent for developing new therapeutic drugs for neurodegenerative diseases.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Osada N, Kosuge Y, Ishige K, Ito Y. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Pharmacol Sci. 2013; 122(4):251-6. Epub 2013 Jul 30.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31644044" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31644044" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60468f68739e6e76371e8286">Plicamycin - LiverTox</a><div class="ralinkpop offscreen_noflow">Plicamycin - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T15:56:09-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal104&amp;ncbi_phid=CE8B35F30466A1110000000007EA0252&amp;ncbi_session=CE8B35F30468F681_2026SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548735%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548735&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548735/&amp;ncbi_pagename=Plicamycin - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8B35F30468F681_2026SID /projects/books/PBooks@9.2 portal104 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>